2022 Highlights:
- Q4 2022 revenue of $51.8 million, an increase of 88% year-over-year.
- Fiscal 2022 Revenue of $211 million, representing full-year growth of 239%.
- Reached a new Company record of nine launches within a calendar year.
- Achieved a record of 100% mission success for Electron launches for the year.
- Successfully launched CAPSTONE mission to the Moon for NASA, including first demonstration of Lunar Photon spacecraft platform.
Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today shared the financial results for its fiscal fourth quarter and full year 2022, ended December 31, 2022.
Rocket Lab founder and CEO, Peter Beck, said: “Rocket Lab set new company records in 2022. It was our busiest launch year yet with nine Electron launches and 100% mission success. We also made significant progress on the development of Neutron with hardware in production, the launch pad and production complex sites selected and under construction, and an engine test stand at NASA Stennis already supporting the Archimedes test program. It was also a terrific year across space systems, with our strategy to become a full-service space company demonstrated with the successful CAPSTONE mission to the Moon for NASA featuring Rocket Lab developed launch vehicle and spacecraft, and further strengthened with the contract award to develop 17 spacecraft buses for MDA to support Globalstar’s new constellation.”
Fourth Quarter 2022 Business Highlights:
- Launched two successful Electron missions in the fourth quarter for General Atomics and the Swedish National Space Agency.
- Selected by NASA to launch the TROPICS (Time-Resolved Observations of Precipitation Structure and Storm Intensity with a Constellation of Smallsats) mission across two dedicated Electron launches to study hurricanes and tropical storms.
- Introduced the Rocket Lab Responsive Space Program to streamline launch on rapid timelines, delivering confidence and resilience to our customers.
- Completed an ocean recovery of Electron’s first stage, progressing the Company’s program to make Electron a reusable rocket.
- Officially opened the Archimedes engine test stand at NASA’s Stennis Space Center and commenced pre-burner ignitor testing, fast-tracking engine testing for the Neutron rocket.
- Completed construction of the first Neutron Production Complex building at NASA Wallops Flight Facility, began production of carbon composite tank structures and commenced construction on the Neutron launch pad.
- Selected to deliver Satellite Operations Control Center for Globalstar Constellation, building on the $143 million contract awarded in February 2022 to design and manufacture 17 spacecraft buses for Globalstar.
- Selected to build solar panels for NASA’s CADRE mobile robot program.
- Delivered final solar panels for NASA Gateway’s Power and Propulsion Element.
Business Highlights Since December 31, 2022:
- Successfully launched the Company’s first mission from Launch Complex 2 at the Mid-Atlantic Regional Spaceport within NASA’s Wallops Flight Facility in Virginia. The mission deployed three satellites for radio frequency geospatial analytics provider HawkEye 360. With the launch, all three of Rocket Lab’s pads have now successfully launched Electron missions.
- Undertaking simultaneous launch campaigns across Launch Complex 1 in New Zealand and Launch Complex 2 in Virginia with two dedicated Electron missions planned to launch within days of each other in March from two continents.
- Bolstered the Company’s existing line of proven satellite components with the introduction of two new high performance satellite components: a 12Nms reaction wheel designed for constellations and the Frontier-X software defined radio designed to provide high speed data for both near Earth and deep space small satellite missions.
- Formally established Rocket Lab Australia to explore opportunities in launch and space systems.
- Neutron launch vehicle in development now eligible to compete for National Space Security Launch Phase 3 missions – the U.S. Space Force’s program intended to provide assured access to space for Department of Defense and other critical U.S. government payloads.
First Quarter 2023 Guidance
For the first quarter of 2023, Rocket Lab expects:
- Revenue between $51 million and $54 million.
- Launch Services revenue of approximately $19 million.
- Space Systems revenue of between $32 million to $35 million.
- GAAP Gross Margins between -5% to -3%.
- Non-GAAP Gross Margins between 7% to 9%.
- GAAP Operating Expenses between $44 million to $46 million.
- Non-GAAP Operating Expenses between $33 million to $35 million.
- Expected Interest Expense (Income), net $1 million.
- Adjusted EBITDA loss of $28 million to $30 million.
- Basic Shares Outstanding of 476 million.
See “Use of Non-GAAP Financial Measures” below for an explanation of our use of Non-GAAP financial measures, and the reconciliation of historical Non-GAAP measures to the comparable GAAP measures in the tables attached to this press release.We have not provided a reconciliation for the forward-looking Non-GAAP Gross Margin, Non-GAAP Operating Expenses or Adjusted EBITDA expectations for Q1 2023 described above because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. Stock-based compensation is currently expected to range from $12 million to $13 million in Q1 2023.
Rocket Lab also announces that David Cowan will complete his tenure on Rocket Lab’s Board of Directors this quarter after nine years serving the company.
Rocket Lab would like to thank David for his leadership, guidance, and support as the Company grew from a small start-up to a NASDAQ-listed company and globally recognized leader in space.
Conference Call Information
Rocket Lab will host a conference call for investors at 1:30 p.m. PT (4:30 p.m. ET) today to discuss these business highlights and financial results for our fourth quarter, to provide our outlook for the rest of the year, and other updates.
The live webcast and a replay of the webcast will be available on Rocket Lab’s Investor Relations website: https://investors.rocketlabusa.com/events-and-presentations/events
About Rocket Lab
Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle and the Photon satellite platform and is developing the Neutron launch vehicle for large spacecraft and constellation deployment. From its first orbital launch in January 2018 to date, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 155 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch site in Virginia, USA. To learn more, visit www.rocketlabusa.com.
+ FORWARD LOOKING STATEMENTS
This press release may contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this release, including statements regarding our expectations of financial results for the first quarter of 2023, strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Rocket Lab’s current expectations and beliefs concerning future developments and their potential effects. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Rocket Lab’s control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including risks related to delays and disruptions in expansion efforts; our dependence on a limited number of customers; the harsh and unpredictable environment of space in which our products operate which could adversely affect our launch vehicle and spacecraft; increased congestion from the proliferation of low Earth orbit constellations which could materially increase the risk of potential collision with space debris or another spacecraft and limit or impair our launch flexibility and/or access to our own orbital slots; increased competition in our industry due in part to rapid technological development and decreasing costs; technological change in our industry which we may not be able to keep up with or which may render our services uncompetitive; average selling price trends; failure of our launch vehicles, spacecraft and components to operate as intended either due to our error in design in production or through no fault of our own; launch schedule disruptions; supply chain disruptions, product delays or failures; the global COVID-19 pandemic; risks related to government restrictions and lock-downs in New Zealand and other countries in which we operate that could delay or suspend our operations; design and engineering flaws; launch failures; natural disasters and epidemics or pandemics; changes in governmental regulations including with respect to trade and export restrictions, or in the status of our regulatory approvals or applications; or other events that force us to cancel or reschedule launches, including customer contractual rescheduling and termination rights; risks that acquisitions may not be completed on the anticipated time frame or at all or do not achieve the anticipated benefits and results; and the other risks detailed from time to time in Rocket Lab’s filings with the Securities and Exchange Commission (the “SEC”), including under the heading “Risk Factors” in Rocket Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on March 24, 2022, and elsewhere (including that the impact of the COVID-19 pandemic may also exacerbate the risks discussed therein). There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated. Except as required by law, Rocket Lab is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Notes to Editor: All dollar amounts in this press release are expressed in U.S. dollars, unless otherwise stated.
+ USE OF NON-GAAP FINANCIAL MEASURES
We supplement the reporting of our financial information determined under Generally Accepted Accounting Principles in the United States of America (“GAAP”) with certain non-GAAP financial information. The non-GAAP financial information presented excludes certain significant items that may not be indicative of, or are unrelated to, results from our ongoing business operations. We believe that these non-GAAP measures provide investors with additional insight into the company's ongoing business performance. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Reconciliation of the non-GAAP financial information to the corresponding GAAP measures for the historical periods disclosed are included at the end of the tables in this press release. We have not provided a reconciliation for forward-looking non GAAP financial measures because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock based compensation and its related tax effects. The following definitions are provided:
+ ADJUSTED EDITDA
EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from net income or loss to determine Adjusted EBITDA. Management believes this measure provides investors meaningful insight into results from ongoing operations.
+ OTHER NON-GAAP FINANCIAL MEASURES
Non-GAAP gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net, further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from the applicable GAAP financial measure. Management believes these non-GAAP measures provide investors meaningful insight into results from ongoing operations.
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2022 AND 2021
|
|
(unaudited; in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
Three Months Ended December 31,
|
|
Years Ended December 31,
|
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
Revenues
|
|
$
|
51,762
|
|
|
$
|
27,478
|
|
|
$
|
210,996
|
|
|
$
|
62,237
|
|
|
Cost of revenues
|
|
|
49,932
|
|
|
|
20,793
|
|
|
|
192,006
|
|
|
|
64,130
|
|
|
Gross profit (loss)
|
|
|
1,830
|
|
|
|
6,685
|
|
|
|
18,990
|
|
|
|
(1,893
|
)
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Research and development, net
|
|
|
15,018
|
|
|
|
11,968
|
|
|
|
65,168
|
|
|
|
41,765
|
|
|
Selling, general and administrative
|
|
|
24,035
|
|
|
|
19,048
|
|
|
|
89,026
|
|
|
|
58,395
|
|
|
Total operating expenses
|
|
|
39,053
|
|
|
|
31,016
|
|
|
|
154,194
|
|
|
|
100,160
|
|
|
Operating loss
|
|
|
(37,223
|
)
|
|
|
(24,331
|
)
|
|
|
(135,204
|
)
|
|
|
(102,053
|
)
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(892
|
)
|
|
|
(2,751
|
)
|
|
|
(7,799
|
)
|
|
|
(6,128
|
)
|
|
Loss on foreign exchange
|
|
|
(488
|
)
|
|
|
(178
|
)
|
|
|
(4,435
|
)
|
|
|
(567
|
)
|
|
Change in fair value of liability classified warrants
|
|
|
—
|
|
|
|
24,130
|
|
|
|
13,482
|
|
|
|
(15,294
|
)
|
|
Other income (expense), net
|
|
|
385
|
|
|
|
(215
|
)
|
|
|
1,010
|
|
|
|
(798
|
)
|
|
Total other income (expense), net
|
|
|
(995
|
)
|
|
|
20,986
|
|
|
|
2,258
|
|
|
|
(22,787
|
)
|
|
Loss before income taxes
|
|
|
(38,218
|
)
|
|
|
(3,345
|
)
|
|
|
(132,946
|
)
|
|
|
(124,840
|
)
|
|
Benefit (provision) for income taxes
|
|
|
1,010
|
|
|
|
6,541
|
|
|
|
(2,998
|
)
|
|
|
7,520
|
|
|
Net income (loss)
|
|
$
|
(37,208
|
)
|
|
$
|
3,196
|
|
|
$
|
(135,944
|
)
|
|
$
|
(117,320
|
)
|
|
Net income (loss) per share attributable to Rocket Lab USA, Inc.:
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.08
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.29
|
)
|
|
$
|
(0.56
|
)
|
|
Diluted
|
|
$
|
(0.08
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.29
|
)
|
|
$
|
(0.56
|
)
|
|
Weighted-average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
473,644,862
|
|
|
|
449,270,950
|
|
|
|
466,214,095
|
|
|
|
209,895,135
|
|
|
Diluted
|
|
|
473,644,862
|
|
|
|
451,945,594
|
|
|
|
466,214,095
|
|
|
|
209,895,135
|
|
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES
|
|
CONSOLIDATED BALANCE SHEETS
|
|
AS OF DECEMBER 31, 2022 AND 2021
|
|
(unaudited; in thousands, except share and per share data)
|
|
|
|
|
|
December 31,
|
|
|
|
2022
|
|
2021
|
|
Assets
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
242,515
|
|
|
$
|
690,959
|
|
|
Marketable securities, current
|
|
|
229,276
|
|
|
|
—
|
|
|
Accounts receivable, net
|
|
|
36,572
|
|
|
|
13,957
|
|
|
Contract assets
|
|
|
9,451
|
|
|
|
2,490
|
|
|
Inventories
|
|
|
92,279
|
|
|
|
47,904
|
|
|
Prepaids and other current assets
|
|
|
52,201
|
|
|
|
19,454
|
|
|
Total current assets
|
|
|
662,294
|
|
|
|
774,764
|
|
|
Non-current assets:
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
101,514
|
|
|
|
65,339
|
|
|
Intangible assets, net
|
|
|
79,692
|
|
|
|
57,487
|
|
|
Goodwill
|
|
|
71,020
|
|
|
|
43,308
|
|
|
Right-of-use assets - operating leases
|
|
|
35,239
|
|
|
|
28,424
|
|
|
Right-of-use assets - finance leases
|
|
|
15,614
|
|
|
|
—
|
|
|
Marketable securities, non-current
|
|
|
9,193
|
|
|
|
—
|
|
|
Restricted cash
|
|
|
3,356
|
|
|
|
1,116
|
|
|
Deferred income tax assets, net
|
|
|
3,898
|
|
|
|
5,859
|
|
|
Other non-current assets
|
|
|
7,303
|
|
|
|
4,550
|
|
|
Total assets
|
|
$
|
989,123
|
|
|
$
|
980,847
|
|
|
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Trade payables
|
|
$
|
12,084
|
|
|
$
|
3,489
|
|
|
Accrued expenses
|
|
|
8,723
|
|
|
|
10,977
|
|
|
Employee benefits payable
|
|
|
8,634
|
|
|
|
8,266
|
|
|
Contract liabilities
|
|
|
108,344
|
|
|
|
59,749
|
|
|
Current installments of long-term borrowings
|
|
|
2,906
|
|
|
|
2,827
|
|
|
Other current liabilities
|
|
|
22,249
|
|
|
|
10,999
|
|
|
Total current liabilities
|
|
|
162,940
|
|
|
|
96,307
|
|
|
Non-current liabilities:
|
|
|
|
|
|
Long-term borrowings, excluding current installments
|
|
|
100,043
|
|
|
|
97,297
|
|
|
Non-current operating lease liabilities
|
|
|
34,266
|
|
|
|
28,302
|
|
|
Non-current finance lease liabilities
|
|
|
15,568
|
|
|
|
—
|
|
|
Deferred tax liabilities
|
|
|
95
|
|
|
|
466
|
|
|
Public and private warrant liabilities
|
|
|
—
|
|
|
|
58,227
|
|
|
Other non-current liabilities
|
|
|
3,005
|
|
|
|
1,800
|
|
|
Total liabilities
|
|
|
315,917
|
|
|
|
282,399
|
|
|
COMMITMENTS AND CONTINGENCIES
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
Common stock, $0.0001 par value; authorized shares: 2,500,000,000; issued and outstanding shares: 475,356,517 and 450,180,479 at December 31, 2022 and December 31, 2021, respectively
|
|
|
48
|
|
|
|
45
|
|
|
Additional paid-in capital
|
|
|
1,112,977
|
|
|
|
1,002,106
|
|
|
Accumulated deficit
|
|
|
(440,955
|
)
|
|
|
(305,011
|
)
|
|
Accumulated other comprehensive income
|
|
|
1,136
|
|
|
|
1,308
|
|
|
Total stockholders’ equity
|
|
|
673,206
|
|
|
|
698,448
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
989,123
|
|
|
$
|
980,847
|
|
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
|
|
(unaudited; in thousands)
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2022
|
|
2021
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
Net loss
|
|
$
|
(135,944
|
)
|
|
$
|
(117,320
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
Depreciation and amortization
|
|
|
29,947
|
|
|
|
10,851
|
|
|
Stock-based compensation expense
|
|
|
55,649
|
|
|
|
32,557
|
|
|
Loss on disposal of assets
|
|
|
923
|
|
|
|
156
|
|
|
Loss on extinguishment of long-term debt
|
|
|
—
|
|
|
|
496
|
|
|
Amortization of debt issuance costs and discount
|
|
|
2,827
|
|
|
|
1,546
|
|
|
Noncash lease expense
|
|
|
3,199
|
|
|
|
2,010
|
|
|
Noncash (income) expense associated with liability-classified warrants
|
|
|
(13,482
|
)
|
|
|
15,294
|
|
|
Accretion of marketable securities purchased at a discount
|
|
|
(1,395
|
)
|
|
|
—
|
|
|
Deferred income taxes
|
|
|
(576
|
)
|
|
|
(9,979
|
)
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
Accounts receivable, net
|
|
|
(9,430
|
)
|
|
|
(7,789
|
)
|
|
Contract assets
|
|
|
(7,545
|
)
|
|
|
1,816
|
|
|
Inventories
|
|
|
(25,964
|
)
|
|
|
(12,072
|
)
|
|
Prepaids and other current assets
|
|
|
(15,059
|
)
|
|
|
(10,504
|
)
|
|
Other non-current assets
|
|
|
(7,072
|
)
|
|
|
(4,548
|
)
|
|
Trade payables
|
|
|
(2,129
|
)
|
|
|
(4,517
|
)
|
|
Accrued expenses
|
|
|
(3,518
|
)
|
|
|
3,074
|
|
|
Employee benefits payables
|
|
|
2,108
|
|
|
|
(326
|
)
|
|
Contract liabilities
|
|
|
22,661
|
|
|
|
28,057
|
|
|
Other current liabilities
|
|
|
1,280
|
|
|
|
838
|
|
|
Non-current lease liabilities
|
|
|
(3,686
|
)
|
|
|
(1,801
|
)
|
|
Other non-current liabilities
|
|
|
668
|
|
|
|
370
|
|
|
Net cash used in operating activities
|
|
|
(106,538
|
)
|
|
|
(71,791
|
)
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
Purchases of property, equipment and software
|
|
|
(42,412
|
)
|
|
|
(25,699
|
)
|
|
Cash paid for acquisitions, net of acquired cash and restricted cash
|
|
|
(65,824
|
)
|
|
|
(66,435
|
)
|
|
Purchases of marketable securities
|
|
|
(259,567
|
)
|
|
|
—
|
|
|
Maturities of marketable securities
|
|
|
21,724
|
|
|
|
—
|
|
|
Net cash used in investing activities
|
|
|
(346,079
|
)
|
|
|
(92,134
|
)
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
Proceeds from the exercise of stock options and public warrants
|
|
|
3,874
|
|
|
|
3,147
|
|
|
Proceeds from Employee Stock Purchase Plan
|
|
|
4,380
|
|
|
|
—
|
|
|
Proceeds from sale of employees restricted stock units to cover taxes
|
|
|
31,166
|
|
|
|
—
|
|
|
Minimum tax withholding paid on behalf of employees for restricted stock units
|
|
|
(31,164
|
)
|
|
|
—
|
|
|
Tax payment for net settled option shares
|
|
|
(444
|
)
|
|
|
—
|
|
|
Payment of contingent consideration
|
|
|
(5,500
|
)
|
|
|
—
|
|
|
Finance lease principal payments
|
|
|
(271
|
)
|
|
|
—
|
|
|
Proceeds from long-term revolving line of credit
|
|
|
—
|
|
|
|
15,000
|
|
|
Proceeds from long-term secured term loan
|
|
|
—
|
|
|
|
98,895
|
|
|
Repayments on long-term revolving line of credit
|
|
|
—
|
|
|
|
(15,000
|
)
|
|
Proceeds from Business Combination and PIPE Investment, net of transaction costs
|
|
|
—
|
|
|
|
728,255
|
|
|
Repurchase of shares and options from management, net of amount recognized as compensation cost
|
|
|
—
|
|
|
|
(30,358
|
)
|
|
Net cash provided by financing activities
|
|
|
2,041
|
|
|
|
799,939
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
4,372
|
|
|
|
2,128
|
|
|
Net increase (decrease) in cash and cash equivalents and restricted cash
|
|
|
(446,204
|
)
|
|
|
638,142
|
|
|
Cash and cash equivalents, and restricted cash, beginning of period
|
|
|
692,075
|
|
|
|
53,933
|
|
|
Cash and cash equivalents, and restricted cash, end of period
|
|
$
|
245,871
|
|
|
$
|
692,075
|
|
|
ROCKET LAB U.S.A., INC. AND SUBSIDIARIES
|
|
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
|
|
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2022 AND 2021
|
|
(unaudited; in thousands)
|
|
|
|
|
|
|
The tables provided below reconcile the non-GAAP financial measures Adjusted EBITDA, Non-GAAP gross profit, Non-GAAP research and development, net, Non-GAAP selling, general and administrative, Non-GAAP operating expenses, Non-GAAP operating loss and Non-GAAP total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures.
|
|
|
|
|
|
|
|
|
Three Months Ended
December 31,
|
|
Years Ended December 31,
|
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
NET INCOME (LOSS)
|
|
$
|
(37,208
|
)
|
|
$
|
3,196
|
|
|
$
|
(135,944
|
)
|
|
$
|
(117,320
|
)
|
|
Depreciation
|
|
|
4,809
|
|
|
|
2,030
|
|
|
|
16,720
|
|
|
|
7,530
|
|
|
Amortization
|
|
|
3,548
|
|
|
|
1,411
|
|
|
|
13,227
|
|
|
|
3,321
|
|
|
Stock-based compensation expense
|
|
|
12,337
|
|
|
|
8,384
|
|
|
|
55,649
|
|
|
|
32,557
|
|
|
Management redemption compensation expense
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
9,724
|
|
|
Transaction costs
|
|
|
144
|
|
|
|
1,836
|
|
|
|
649
|
|
|
|
2,495
|
|
|
Loss on extinguishment of debt
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
795
|
|
|
Interest expense, net
|
|
|
892
|
|
|
|
2,751
|
|
|
|
7,799
|
|
|
|
6,128
|
|
|
Change in fair value of liability classified warrants
|
|
|
—
|
|
|
|
(24,130
|
)
|
|
|
(13,482
|
)
|
|
|
15,294
|
|
|
Change in fair value of contingent consideration
|
|
|
(200
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Performance reserve escrow
|
|
|
1,895
|
|
|
|
1,895
|
|
|
|
7,579
|
|
|
|
1,895
|
|
|
Amortization of inventory step-up
|
|
|
—
|
|
|
|
616
|
|
|
|
2,618
|
|
|
|
616
|
|
|
(Benefit) provision for income taxes
|
|
|
(1,010
|
)
|
|
|
(6,541
|
)
|
|
|
2,998
|
|
|
|
(7,520
|
)
|
|
Loss on foreign exchange
|
|
|
488
|
|
|
|
178
|
|
|
|
4,435
|
|
|
|
567
|
|
|
Accretion of marketable securities and cash equivalents purchased at a discount
|
|
|
(1,092
|
)
|
|
|
—
|
|
|
|
(1,696
|
)
|
|
|
—
|
|
|
Loss on disposal of assets
|
|
|
891
|
|
|
|
93
|
|
|
|
923
|
|
|
|
156
|
|
|
ADJUSTED EBITDA
|
|
$
|
(14,506
|
)
|
|
$
|
(8,281
|
)
|
|
$
|
(38,525
|
)
|
|
$
|
(43,762
|
)
|
|
|
|
Three Months Ended
December 31,
|
|
Years Ended December 31,
|
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
GAAP Gross profit (loss)
|
|
$
|
1,830
|
|
|
$
|
6,685
|
|
|
$
|
18,990
|
|
|
$
|
(1,893
|
)
|
|
Stock-based compensation
|
|
|
3,857
|
|
|
|
2,455
|
|
|
|
17,948
|
|
|
|
10,996
|
|
|
Amortization of purchased intangibles
|
|
|
1,710
|
|
|
|
144
|
|
|
|
4,782
|
|
|
|
312
|
|
|
Amortization of inventory step-up
|
|
|
—
|
|
|
|
616
|
|
|
|
2,618
|
|
|
|
616
|
|
|
Performance reserve escrow
|
|
|
114
|
|
|
|
114
|
|
|
|
456
|
|
|
|
114
|
|
|
Non-GAAP Gross profit (loss)
|
|
$
|
7,511
|
|
|
$
|
10,014
|
|
|
$
|
44,794
|
|
|
$
|
10,145
|
|
|
Non-GAAP Gross margin
|
|
|
14.5
|
%
|
|
|
36.4
|
%
|
|
|
21.2
|
%
|
|
|
16.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Research and development, net
|
|
$
|
15,018
|
|
|
$
|
11,968
|
|
|
$
|
65,168
|
|
|
$
|
41,765
|
|
|
Stock-based compensation
|
|
|
(4,442
|
)
|
|
|
(3,039
|
)
|
|
|
(21,127
|
)
|
|
|
(9,973
|
)
|
|
Amortization of purchased intangibles
|
|
|
(9
|
)
|
|
|
(976
|
)
|
|
|
(3,342
|
)
|
|
|
(2,081
|
)
|
|
Non-GAAP Research and development, net
|
|
$
|
10,567
|
|
|
$
|
7,953
|
|
|
$
|
40,699
|
|
|
$
|
29,711
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Selling, general and administrative
|
|
$
|
24,035
|
|
|
$
|
19,048
|
|
|
$
|
89,026
|
|
|
$
|
58,395
|
|
|
Stock-based compensation
|
|
|
(4,038
|
)
|
|
|
(2,890
|
)
|
|
|
(16,574
|
)
|
|
|
(11,588
|
)
|
|
Management redemption compensation expense
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(9,724
|
)
|
|
Amortization of purchased intangibles
|
|
|
(1,494
|
)
|
|
|
(113
|
)
|
|
|
(4,401
|
)
|
|
|
(185
|
)
|
|
Transaction costs
|
|
|
(144
|
)
|
|
|
(1,836
|
)
|
|
|
(649
|
)
|
|
|
(2,495
|
)
|
|
Performance reserve escrow
|
|
|
(1,780
|
)
|
|
|
(1,781
|
)
|
|
|
(7,123
|
)
|
|
|
(1,781
|
)
|
|
Change in fair value of contingent consideration
|
|
|
200
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Non-GAAP Selling, general and administrative
|
|
$
|
16,779
|
|
|
$
|
12,428
|
|
|
$
|
60,279
|
|
|
$
|
32,622
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Operating expenses
|
|
$
|
39,053
|
|
|
$
|
31,016
|
|
|
$
|
154,194
|
|
|
$
|
100,160
|
|
|
Stock-based compensation
|
|
|
(8,480
|
)
|
|
|
(5,929
|
)
|
|
|
(37,701
|
)
|
|
|
(21,561
|
)
|
|
Management redemption compensation expense
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(9,724
|
)
|
|
Amortization of purchased intangibles
|
|
|
(1,503
|
)
|
|
|
(1,089
|
)
|
|
|
(7,743
|
)
|
|
|
(2,266
|
)
|
|
Transaction costs
|
|
|
(144
|
)
|
|
|
(1,836
|
)
|
|
|
(649
|
)
|
|
|
(2,495
|
)
|
|
Performance reserve escrow
|
|
|
(1,780
|
)
|
|
|
(1,781
|
)
|
|
|
(7,123
|
)
|
|
|
(1,781
|
)
|
|
Change in fair value of contingent consideration
|
|
|
200
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Non-GAAP Operating expenses
|
|
$
|
27,346
|
|
|
$
|
20,381
|
|
|
$
|
100,978
|
|
|
$
|
62,333
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Operating loss
|
|
$
|
(37,223
|
)
|
|
$
|
(24,331
|
)
|
|
$
|
(135,204
|
)
|
|
$
|
(102,053
|
)
|
|
Total non-GAAP adjustments
|
|
|
17,388
|
|
|
|
13,964
|
|
|
|
79,020
|
|
|
|
49,865
|
|
|
Non-GAAP Operating loss
|
|
$
|
(19,835
|
)
|
|
$
|
(10,367
|
)
|
|
$
|
(56,184
|
)
|
|
$
|
(52,188
|
)
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Total other income (expense), net
|
|
$
|
(995
|
)
|
|
$
|
20,986
|
|
|
$
|
2,258
|
|
|
$
|
(22,787
|
)
|
|
Change in fair value of liability classified warrants
|
|
|
—
|
|
|
|
(24,130
|
)
|
|
|
(13,482
|
)
|
|
|
15,294
|
|
|
Loss on foreign exchange
|
|
|
488
|
|
|
|
178
|
|
|
|
4,435
|
|
|
|
567
|
|
|
Non-GAAP Total other income (expense), net
|
|
$
|
(507
|
)
|
|
$
|
(2,966
|
)
|
|
$
|
(6,789
|
)
|
|
$
|
(6,926
|
)
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006307/en/